Hemolytic Activity of Nanoparticles as a Marker of Their Hemocompatibility
The potential use of nanomaterials in medicine offers opportunities for novel therapeutic approaches to treating complex disorders. For that reason, a new branch of science, named nanotoxicology, which aims to study the dangerous effects of nanomaterials on human health and on the environment, has r...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Micromachines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-666X/13/12/2091 |
| _version_ | 1797456238154350592 |
|---|---|
| author | Saul Yedgar Gregory Barshtein Alexander Gural |
| author_facet | Saul Yedgar Gregory Barshtein Alexander Gural |
| author_sort | Saul Yedgar |
| collection | DOAJ |
| description | The potential use of nanomaterials in medicine offers opportunities for novel therapeutic approaches to treating complex disorders. For that reason, a new branch of science, named nanotoxicology, which aims to study the dangerous effects of nanomaterials on human health and on the environment, has recently emerged. However, the toxicity and risk associated with nanomaterials are unclear or not completely understood. The development of an adequate experimental strategy for assessing the toxicity of nanomaterials may include a rapid/express method that will reliably, quickly, and cheaply make an initial assessment. One possibility is the characterization of the hemocompatibility of nanomaterials, which includes their hemolytic activity as a marker. In this review, we consider various factors affecting the hemolytic activity of nanomaterials and draw the reader’s attention to the fact that the formation of a protein corona around a nanoparticle can significantly change its interaction with the red cell. This leads us to suggest that the nanomaterial hemolytic activity in the buffer does not reflect the situation in the blood plasma. As a recommendation, we propose studying the hemocompatibility of nanomaterials under more physiologically relevant conditions, in the presence of plasma proteins in the medium and under mechanical stress. |
| first_indexed | 2024-03-09T16:05:22Z |
| format | Article |
| id | doaj.art-9a47bc4a5a24426f967a0631ef2e5546 |
| institution | Directory Open Access Journal |
| issn | 2072-666X |
| language | English |
| last_indexed | 2024-03-09T16:05:22Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Micromachines |
| spelling | doaj.art-9a47bc4a5a24426f967a0631ef2e55462023-11-24T16:44:01ZengMDPI AGMicromachines2072-666X2022-11-011312209110.3390/mi13122091Hemolytic Activity of Nanoparticles as a Marker of Their HemocompatibilitySaul Yedgar0Gregory Barshtein1Alexander Gural2Department of Biochemistry, The Faculty of Medicine, Hebrew University, Jerusalem 91120, IsraelDepartment of Biochemistry, The Faculty of Medicine, Hebrew University, Jerusalem 91120, IsraelBlood Bank, Hadassah-Hebrew University Medical Center, Jerusalem 91120, IsraelThe potential use of nanomaterials in medicine offers opportunities for novel therapeutic approaches to treating complex disorders. For that reason, a new branch of science, named nanotoxicology, which aims to study the dangerous effects of nanomaterials on human health and on the environment, has recently emerged. However, the toxicity and risk associated with nanomaterials are unclear or not completely understood. The development of an adequate experimental strategy for assessing the toxicity of nanomaterials may include a rapid/express method that will reliably, quickly, and cheaply make an initial assessment. One possibility is the characterization of the hemocompatibility of nanomaterials, which includes their hemolytic activity as a marker. In this review, we consider various factors affecting the hemolytic activity of nanomaterials and draw the reader’s attention to the fact that the formation of a protein corona around a nanoparticle can significantly change its interaction with the red cell. This leads us to suggest that the nanomaterial hemolytic activity in the buffer does not reflect the situation in the blood plasma. As a recommendation, we propose studying the hemocompatibility of nanomaterials under more physiologically relevant conditions, in the presence of plasma proteins in the medium and under mechanical stress.https://www.mdpi.com/2072-666X/13/12/2091nanomaterialsnanoparticlesred blood cellshemocompatibilitynanotoxicityhemolytic activity |
| spellingShingle | Saul Yedgar Gregory Barshtein Alexander Gural Hemolytic Activity of Nanoparticles as a Marker of Their Hemocompatibility Micromachines nanomaterials nanoparticles red blood cells hemocompatibility nanotoxicity hemolytic activity |
| title | Hemolytic Activity of Nanoparticles as a Marker of Their Hemocompatibility |
| title_full | Hemolytic Activity of Nanoparticles as a Marker of Their Hemocompatibility |
| title_fullStr | Hemolytic Activity of Nanoparticles as a Marker of Their Hemocompatibility |
| title_full_unstemmed | Hemolytic Activity of Nanoparticles as a Marker of Their Hemocompatibility |
| title_short | Hemolytic Activity of Nanoparticles as a Marker of Their Hemocompatibility |
| title_sort | hemolytic activity of nanoparticles as a marker of their hemocompatibility |
| topic | nanomaterials nanoparticles red blood cells hemocompatibility nanotoxicity hemolytic activity |
| url | https://www.mdpi.com/2072-666X/13/12/2091 |
| work_keys_str_mv | AT saulyedgar hemolyticactivityofnanoparticlesasamarkeroftheirhemocompatibility AT gregorybarshtein hemolyticactivityofnanoparticlesasamarkeroftheirhemocompatibility AT alexandergural hemolyticactivityofnanoparticlesasamarkeroftheirhemocompatibility |